2 weeks Ago By ABMN Staff
Townsquare Capital LLC lowered its stake in shares of Biogen Inc. ( NASDAQ:BIIB – Free Report ) by 78.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission.
The institutional investor owned 2,811 shares of the biotechnology company’s stock after selling 9,997 shares during the quarter. Townsquare Capital LLC’s holdings in Biogen were worth $430,000 at the end of the most recent quarter. Several other large investors have also bought and sold shares of BIIB.
Virtu Financial LLC purchased a new position in Biogen during the third quarter worth about $4,111,000. World Investment Advisors LLC bought a new position in shares of Biogen in the third quarter valued at approximately $1,118,000. Wilmington Savings Fund Society FSB bought a new stake in Biogen during the third quarter worth $150,000.
Tidal Investments LLC boosted its position in Biogen by 13.6% in the third quarter. Tidal Investments LLC now owns 9,012 shares of the biotechnology company’s stock worth $1,747,000 after purchasing an additional 1,082 shares during the last quarter.
Finally, Synovus Financial Corp increased its position in shares of Biogen by 6.0% during the 3rd quarter. Synovus Financial Corp now owns 14,462 shares of the biotechnology company’s stock valued at $2,803,000 after purchasing an additional 821 shares during the last quarter.
87.93% of the stock is currently owned by institutional investors. Analyst Upgrades and Downgrades Several research firms recently weighed in on BIIB.
Morgan Stanley reduced their price target on shares of Biogen from $157.00 to $152.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 9th.
The Goldman Sachs Group dropped their price objective on Biogen from $281.00 to $245.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th.
Canaccord Genuity Group lowered their target price on Biogen from $298.00 to $265.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th.
Bank Of America (Bofa) decreased their price objective on Biogen from $178.00 to $163.00 and set a “neutral” rating for the company in a report on Tuesday, February 11th.
Finally, BMO Capital Markets dropped their price objective on shares of Biogen from $156.00 to $139.00 and set a “market perform” rating on the stock in a report on Thursday, February 13th.
Eighteen equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Biogen presently has a consensus rating of “Hold” and an average price target of $213.15.
Biogen Stock Up 2.9 % Shares of NASDAQ BIIB opened at $118.61 on Monday.
The stock has a market capitalization of $17.36 billion, a P/E ratio of 10.60, a PEG ratio of 1.
51 and a beta of 0.06. The company has a debt-to-equity ratio of 0.
27, a current ratio of 1.35 and a quick ratio of 0.90.
Biogen Inc. has a one year low of $110.04 and a one year high of $238.
00. The firm’s 50 day simple moving average is $134.29 and its two-hundred day simple moving average is $151.
20. Biogen ( NASDAQ:BIIB – Get Free Report ) last issued its earnings results on Wednesday, February 12th. The biotechnology company reported $3.
44 EPS for the quarter, topping analysts’ consensus estimates of $3.43 by $0.01.
Biogen had a net margin of 16.87% and a return on equity of 14.98%.
As a group, analysts expect that Biogen Inc. will post 15.83 EPS for the current fiscal year.
Insider Activity at Biogen In related news, Director Stephen A. Sherwin sold 8,760 shares of the company’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $150.
02, for a total transaction of $1,314,175.20. Following the completion of the sale, the director now directly owns 11,318 shares in the company, valued at $1,697,926.
36. This represents a 43.63 % decrease in their position.
The transaction was disclosed in a filing with the SEC, which is available through this link . 0.16% of the stock is currently owned by company insiders.
Biogen Company Profile ( Free Report ) Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. Featured Articles Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Biogen Inc. ( NASDAQ:BIIB – Free Report ). Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.
com's FREE daily email newsletter ..
